Aptorum Group Net Cash Flow 2018-2024 | APM

Aptorum Group net cash flow from 2018 to 2024. Net cash flow can be defined as the total change in cash for the company over the given period.

Aptorum Group Net Cash Flow 2018-2024 | APM

Aptorum Group net cash flow from 2018 to 2024. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$67.5B
Zoetis (ZTS)$66B
Daiichi Sankyo, - (DSNKY)$46.3B
Takeda Pharmaceutical (TAK)$45.9B
BeOne Medicines - (ONC)$31.8B
Sandoz Group AG (SDZNY)$25.5B
Summit Therapeutics (SMMT)$21B
Merck (MKKGY)$16.3B
Shionogi (SGIOY)$15.2B
United Therapeutics (UTHR)$13.6B
Neurocrine Biosciences (NBIX)$12.3B
Orion OYJ (ORINY)$10.8B
IPSEN (IPSEY)$10.4B
Madrigal Pharmaceuticals (MDGL)$7.8B
Corcept Therapeutics (CORT)$7.6B
Grifols, S.A (GRFS)$7.3B
Stevanato Group S.p.A (STVN)$6.6B
Ionis Pharmaceuticals (IONS)$6.5B
Hikma Pharmaceuticals Plc (HKMPF)$5.3B
Ono Pharmaceutical (OPHLF)$5.1B
Soleno Therapeutics (SLNO)$4.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.8B
NewAmsterdam Pharma (NAMS)$2.7B
Hypermarcas (HYPMY)$2.7B
Crinetics Pharmaceuticals (CRNX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.4B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$2.2B
Endo (NDOI)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.7B